{"nctId":"NCT00049673","briefTitle":"Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma","startDateStruct":{"date":"2002-10-15","type":"ACTUAL"},"conditions":["Multiple Myeloma and Plasma Cell Neoplasm"],"count":332,"armGroups":[{"label":"Arm I","type":"EXPERIMENTAL","interventionNames":["Drug: prednisone","Drug: thalidomide"]},{"label":"Arm II","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"prednisone","otherNames":[]},{"name":"thalidomide","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed multiple myeloma as evidenced by one of the following:\n\n  * Biopsy of an osteolytic lesion or soft tissue tumor composed of plasma cells\n  * Bone marrow aspirate and/or biopsy demonstrating at least 10% plasmacytosis\n  * Bone marrow less than 10% plasma cells with at least 1 bony lesion and meets the M-protein criteria as below\n* Detectable serum M-component of IgG, IgA, IgD, or IgE at initial diagnosis OR\n* Urinary excretion of light chain (Bence Jones) protein at least 1.0 gm/24 hrs if only light chain disease (urine M-protein) was present at initial diagnosis\n* Previously treated with autologous stem cell transplantation after high-dose melphalan (200 mg/m\\^2) within the past 60-100 days\n\n  * Received transplantation within 1 year of the beginning of initial chemotherapy for multiple myeloma\n  * No evidence of disease progression\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 16 and over\n\nPerformance status\n\n* ECOG 0-2\n\nLife expectancy\n\n* At least 6 months\n\nHematopoietic\n\n* No prior hereditary hypercoaguable disorder\n* Granulocyte count at least 1,000/mm\\^3\n* Platelet count at least 75,000/mm\\^3\n\nHepatic\n\n* Bilirubin no greater than 2 times upper limit of normal (ULN)\n* AST and/or ALT no greater than 2 times ULN\n* Alkaline phosphatase no greater than 2 times ULN\n\nRenal\n\n* Creatinine no greater than 3 times ULN\n\nCardiovascular\n\n* No prior spontaneous deep vein thrombosis within the past 5 years\n\n  * Catheter-associated thrombus allowed\n* No uncontrolled hypertension\n\nPulmonary\n\n* No prior pulmonary embolism within the past 5 years\n\nOther\n\n* No other prior or concurrent malignancy except adequately treated squamous cell or basal cell skin cancer or carcinoma in situ of the cervix or any cancer treated more than 5 years prior to study entry and presumed cured\n* No prior gastric ulceration or bleeding within the past 5 years\n* No prior documented lupus anti-coagulant or anti-phospholipid antibody\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile female patients must use 2 effective methods of contraception for 1 month prior, during, and 1 month after study participation\n* Male patients must use effective barrier contraception during and for 1 month after study participation\n* No avascular necrosis of the hips or shoulders\n* No grade 2 or greater peripheral neuropathy causing symptomatic dysfunction (vincristine-induced sensory symptoms allowed)\n* No diabetes with end-organ damage defined as:\n\n  * Documented diabetic neuropathy\n  * Retinal vascular proliferation requiring treatment\n  * Cardiovascular disease requiring active therapy\n* Willing to complete quality of life questionnaires\n* Employment does not prohibit the use of sedatives\n* No other major medical illness or condition that would preclude study participation\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* See Disease Characteristics\n* No prior double autologous or allogeneic hematopoietic stem cell transplantation\n* No prior thalidomide\n\nChemotherapy\n\n* See Disease Characteristics\n\nEndocrine therapy\n\n* Not specified\n\nRadiotherapy\n\n* Not specified\n\nSurgery\n\n* Not specified\n\nOther\n\n* No other concurrent anti-cancer therapy\n* No other concurrent investigational therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"Number of patients died from any cause during the study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"61","spread":null}]},{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"105","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Progression-free Survival","description":"Number of patients with disease progression or death","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"127","spread":null}]},{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":165},"commonTop":["Bone pain","Neuropathy-sensory","Fatigue","Infection w/o neutropen","Constipation"]}}}